| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| rp150291-10μg | 10μg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $69.90 | |
| rp150291-50μg | 50μg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $279.90 | |
| rp150291-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $449.90 | |
| rp150291-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,569.90 |
Animal Free, >90% (SDS-PAGE), Active, HEK293, C-His tag, 22-441 aa
| Product Name | Recombinant Human PLA2G7 Protein, ＞90% (SDS-PAGE), high purityused for Active,SDS-PAGE various applications |
|---|---|
| Synonyms | 2-acetyl-1-alkylglycerophosphocholine esterase | EC 3.1.1 | EC 3.1.1.47,1-alkyl-2-acetylglycerophosphocholine esterase | Group-VIIA phospholipase A2 | gVIIA-PLA2 | LDL-associated phospholipase A2 | LDL-PLA(2) | LDL-PLA2 | lipoprotein-associated phospholip |
| Grade | ActiBioPure™, Animal Free, Azide Free, Bioactive, Carrier Free |
| Product Description | Purity >90% (SDS-PAGE) Function Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. |
| Specifications & Purity | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥90%(SDS-PAGE) |
| Purity | ＞90% (SDS-PAGE) |
| Bioactivity | Measured by its ability to cleave a colorimetric peptide substrate, 1O-hexadecyl-2-deoxy-2-thio Sacetylsnglyceryl-3-phosphoryl choline (2- Thio-PAF), in the presence of 5, 5’Dithiobis(2-nitrobenzoic acid) (DTNB). The specific activity is >5000 pmoles/min/ |
| Endotoxin Concentration | <1.0 EU/μg |
| Expression System | HEK293 |
| Species | Human |
| Amino Acids | 22-441 aa |
| Sequence | FDWQYINPVAHMKSSAWVNKIQVLMAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHIMLQNSSGIEKYNAHHHHHHHHHH |
| Protein Tag | C-His |
| Protein Length | Full length protein |
| Source | Recombinant |
| Predicted molecular weight | 49.2 kDa |
| SDS-PAGE | 50-55 kDa, under reducing conditions |
| Note | 20μg卖完停产，不再备货 |
Recombinant Human PLA2G7 Protein (rp150291) - Enzyme Activity
Measured by its ability to cleave a colorimetric peptide substrate, 1-O-hexadecyl-2-deoxy-2-thio-S-acetyl-sn-glyceryl-3-phosphorylcholine (2-Thio-PAF) (T334670), in the presence of 5,5’Dithio-bis(2-nitrobenzoic acid) (DTNB) (D425581). The specific activity is >5,000 pmol/min/ug, as measured under the described condition.
Recombinant Human PLA2G7 Protein (rp150291) - SDS-PAGE
3 μg/lane of Recombinant Human PLA2G7 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 54.2 kDa.
| Application | Active,SDS-PAGE |
|---|---|
| Form | Lyophilized |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.27mg/mL. |
| Storage Temp | Store at -20°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store it under sterile conditions at -20℃ to -80℃ upon receiving. Upon delivery aliquot. Avoid freeze/thaw cycle. |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F0900996 | Certificate of Analysis | Sep 11, 2023 | rp150291 |
| ZJ23F0900997 | Certificate of Analysis | Sep 11, 2023 | rp150291 |
| 1. Wilensky RL, Macphee CH. (2009) Lipoprotein-associated phospholipase A(2) and atherosclerosis.. Curr Opin Lipidol, 20 (5): (415-20). [PMID:19667981] [10.1021/op500134e] |
| 2. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr J, Hopkin JM et al.. (2000) The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.. Am J Hum Genet, 66 (5): (1522-30). [PMID:10733466] [10.1021/op500134e] |
| 3. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S, Le Trong H, Cousens LS, Zimmerman GA et al.. (1995) Anti-inflammatory properties of a platelet-activating factor acetylhydrolase.. Nature, 374 (6522): (549-53). [PMID:7700381] [10.1021/op500134e] |
| 4. Woolford AJ, Day PJ, Bénéton V, Berdini V, Coyle JE, Dudit Y, Grondin P, Huet P, Lee LY, Manas ES et al.. (2016) Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).. J Med Chem, 59 (23): (10738-10749). [PMID:27933945] [10.1021/op500134e] |
| 5. Liu Q, Huang F, Yuan X, Wang K, Zou Y, Shen J, Xu Y. (2017) Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.. J Med Chem, 60 (24): (10231-10244). [PMID:29193967] [10.1021/op500134e] |
| 6. Hoover HS, Blankman JL, Niessen S, Cravatt BF. (2008) Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling.. Bioorg Med Chem Lett, 18 (22): (5838-41). [PMID:18657971] [10.1021/op500134e] |
| 7. Diana M Stafforini,James R Sheller,Timothy S Blackwell,Adam Sapirstein,Fiona E Yull,Thomas M McIntyre,Joseph V Bonventre,Stephen M Prescott,L Jackson Roberts. (2005-12-24) Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases.. The Journal of biological chemistry, 281 ((8)): (4616-4623). [PMID:16371369] |
| 8. Xinde Chen,Wenwei Xu,Kai Wang,Mingguang Mo,Wei Zhang,Lili Du,Xiaojing Yuan,Yechun Xu,Yiping Wang,Jianhua Shen. (2015-10-20) Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.. Journal of medicinal chemistry, 58 ((21)): (8529-8541). [PMID:26479945] |
| 9. Chen X, Wang K, Xu W, Ma Q, Chen M, Du L, Mo M, Wang Y, Shen J.. (2016) Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.. J Med Chem, 59 (6): (2674-2687). [PMID:26927682] [10.1021/acs.jmedchem.5b01930] |
| 10. Woolford AJ, Pero JE, Aravapalli S, Berdini V, Coyle JE, Day PJ, Dodson AM, Grondin P, Holding FP, Lee LY, Li P, Manas ES, Marino J, Martin AC, McCleland BW, McMenamin RL, Murray CW, Neipp CE, Page LW, Patel VK, Potvain F, Rich S, Rivero RA, Smith K, Somers DO, Trottet L, Velagaleti R, Williams G, Xie R.. (2016) Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.. J Med Chem, 59 (11): (5356-5367). [PMID:27167608] [10.1021/acs.jmedchem.6b00212] |
| 11. Liu Q, Chen X, Chen W, Yuan X, Su H, Shen J, Xu Y.. (2016) Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.. J Med Chem, 59 (10): (5115-5120). [PMID:27078579] [10.1021/acs.jmedchem.6b00282] |
| 12. Tjoelker, L W LW and 8 more authors.. (1995) Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad.. The Journal of biological chemistry, (27): [PMID:7592717] |
| 13. Tew, D G DG and 8 more authors.. (1996) Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins.. Arteriosclerosis, thrombosis, and vascular biology, [PMID:8624782] |
| 14. Stafforini, D M DM and 11 more authors.. (1996) Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.. The Journal of clinical investigation, (15): [PMID:8675689] |
| 15. Yamada, Y Y and Yokota, M M.. (1997) Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.. Biochemical and biophysical research communications, (30): [PMID:9245731] |
| 16. Hiramoto, M M, Yoshida, H H, Imaizumi, T T, Yoshimizu, N N and Satoh, K K.. (1997) A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke.. Stroke, [PMID:9412624] |
| 17. Yamada, Y Y, Ichihara, S S, Fujimura, T T and Yokota, M M.. (1998) Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.. Metabolism: clinical and experimental, [PMID:9472966] |
| 18. Yoshida, H H and 7 more authors.. (1998) A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.. Thrombosis and haemostasis, [PMID:9759612] |
| 19. Kriska, Tamas T, Marathe, Gopal K GK, Schmidt, Jacob C JC, McIntyre, Thomas M TM and Girotti, Albert W AW.. (2007) Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides.. The Journal of biological chemistry, (5): [PMID:17090529] |
| 20. Gardner, Alison A AA, Reichert, Ethan C EC, Topham, Matthew K MK and Stafforini, Diana M DM.. (2008) Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein.. The Journal of biological chemistry, (20): [PMID:18434304] |
| 21. Samanta, Uttamkumar U and Bahnson, Brian J BJ.. (2008) Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis.. The Journal of biological chemistry, (14): [PMID:18784071] |
| 22. Samanta, Uttamkumar; Kirby, Stephen D; Srinivasan, Prabhavathi; Cerasoli, Douglas M and Bahnson, Brian J.. (2009) Crystal structures of human group-VIIA phospholipase A2 inhibited by organophosphorus nerve agents exhibit non-aged complexes.. Biochemical pharmacology, (15): [PMID:19394314] |
